These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 26514402)

  • 1. Purinergic contribution to amyotrophic lateral sclerosis.
    Volonté C; Apolloni S; Parisi C; Amadio S
    Neuropharmacology; 2016 May; 104():180-93. PubMed ID: 26514402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purinergic signalling in brain ischemia.
    Pedata F; Dettori I; Coppi E; Melani A; Fusco I; Corradetti R; Pugliese AM
    Neuropharmacology; 2016 May; 104():105-30. PubMed ID: 26581499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CNS remyelination as a novel reparative approach to neurodegenerative diseases: The roles of purinergic signaling and the P2Y-like receptor GPR17.
    Fumagalli M; Lecca D; Abbracchio MP
    Neuropharmacology; 2016 May; 104():82-93. PubMed ID: 26453964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purinergic receptors as potential therapeutic targets in Alzheimer's disease.
    Woods LT; Ajit D; Camden JM; Erb L; Weisman GA
    Neuropharmacology; 2016 May; 104():169-79. PubMed ID: 26519903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis.
    Gandelman M; Peluffo H; Beckman JS; Cassina P; Barbeito L
    J Neuroinflammation; 2010 Jun; 7():33. PubMed ID: 20534165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATPergic signalling during seizures and epilepsy.
    Engel T; Alves M; Sheedy C; Henshall DC
    Neuropharmacology; 2016 May; 104():140-53. PubMed ID: 26549853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration.
    Burnstock G
    Neuropharmacology; 2016 May; 104():4-17. PubMed ID: 26056033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purinergic mechanisms in neuroinflammation: An update from molecules to behavior.
    Beamer E; Gölöncsér F; Horváth G; Bekő K; Otrokocsi L; Koványi B; Sperlágh B
    Neuropharmacology; 2016 May; 104():94-104. PubMed ID: 26384652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rethinking purinergic concepts and updating the emerging role of P2X7 and P2X4 in amyotrophic lateral sclerosis.
    Volonté C; Amadio S
    Neuropharmacology; 2022 Dec; 221():109278. PubMed ID: 36202258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis.
    D'Ambrosi N; Finocchi P; Apolloni S; Cozzolino M; Ferri A; Padovano V; Pietrini G; Carrì MT; Volonté C
    J Immunol; 2009 Oct; 183(7):4648-56. PubMed ID: 19734218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purinergic receptors in psychiatric disorders.
    Krügel U
    Neuropharmacology; 2016 May; 104():212-25. PubMed ID: 26518371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALS: focus on purinergic signalling.
    Volonté C; Apolloni S; Carrì MT; D'Ambrosi N
    Pharmacol Ther; 2011 Oct; 132(1):111-22. PubMed ID: 21704075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis.
    Apolloni S; Parisi C; Pesaresi MG; Rossi S; Carrì MT; Cozzolino M; Volonté C; D'Ambrosi N
    J Immunol; 2013 May; 190(10):5187-95. PubMed ID: 23589615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of purinergic P2X7 receptor expression and intracellular calcium dysregulation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis.
    Liu J; Prell T; Stubendorff B; Keiner S; Ringer T; Gunkel A; Tadic V; Goldhammer N; Malci A; Witte OW; Grosskreutz J
    Neurosci Lett; 2016 Sep; 630():77-83. PubMed ID: 27453058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purinergic signalling at the plasma membrane: a multipurpose and multidirectional mode to deal with amyotrophic lateral sclerosis and multiple sclerosis.
    Amadio S; Apolloni S; D'Ambrosi N; Volonté C
    J Neurochem; 2011 Mar; 116(5):796-805. PubMed ID: 21214557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purinergic signaling in kidney disease.
    Menzies RI; Tam FW; Unwin RJ; Bailey MA
    Kidney Int; 2017 Feb; 91(2):315-323. PubMed ID: 27780585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane compartments and purinergic signalling: P2X receptors in neurodegenerative and neuroinflammatory events.
    Apolloni S; Montilli C; Finocchi P; Amadio S
    FEBS J; 2009 Jan; 276(2):354-64. PubMed ID: 19076216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2Y(12) receptor on the verge of a neuroinflammatory breakdown.
    Amadio S; Parisi C; Montilli C; Carrubba AS; Apolloni S; Volonté C
    Mediators Inflamm; 2014; 2014():975849. PubMed ID: 25180027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives.
    Cieślak M; Roszek K; Wujak M
    Purinergic Signal; 2019 Mar; 15(1):1-15. PubMed ID: 30430356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purinergic receptors in embryonic and adult neurogenesis.
    Oliveira Á; Illes P; Ulrich H
    Neuropharmacology; 2016 May; 104():272-81. PubMed ID: 26456352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.